Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on autologous CAR-T cell immunotherapies targeting oncology indications. The company reached public markets through a SPAC business combination that closed in 2023, placing it within the life sciences and biotechnology sector. Its August 2023 Form 8-K filing, bearing accession number 0001213900-23-069046, represents a current report submitted to the SEC following the completion of its de-SPAC transaction. As a post-merger entity, ESLA continues to advance its pipeline under the scrutiny of public-market reporting obligations. For complete filing history, sponsor details, and deal timeline data on ESLA and hundreds of other SPAC transactions, sign up for full access at SpacDesk.